Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kamuvudine-8 in Diabetic Macular Edema
NCT05699759Phase 1Completed
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of kamuvudine-8 in diabetic macular edema (DME). Primary endpoints: Mean change in central subfield thickness at 4 weeks, Mean change in best-corrected visual acuity at 4 weeks and 1 more. Started Jan 2024; status: completed.
02
Drugs
kamuvudine-8
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05699759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05699759.